SEC Comment Letter for Avantor, Inc. (AVTR) (CIK 0001722482) (AVTR) — Feb 5, 2020

Avantor, Inc. (AVTR) (CIK 0001722482)
Date: Feb. 5, 2020 · CIK: 0001722482 · Accession: 0000000000-20-001143

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

February 5, 2020

Author

Michael Stubblefield

Form

UPLOAD

Company

Avantor, Inc. (AVTR) (CIK 0001722482)

Letter

February 5, 2020 Michael Stubblefield President and Chief Executive Officer Avantor, Inc. Radnor Corporate Center Building One, Suite 200 100 Matsonford Road Radnor, PA 19087 Re:Avantor, Inc. Draft Registration Statement on Form F-1 Submitted January 30, 2020 CIK No. 0001722482 Dear Mr. Stubblefield: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joseph Kaufman

Show Raw Text

February 5, 2020
Michael Stubblefield
President and Chief Executive Officer
Avantor, Inc.
Radnor Corporate Center
Building One, Suite 200
100 Matsonford Road
Radnor, PA 19087
Re:Avantor, Inc.
Draft Registration Statement on Form F-1
Submitted January 30, 2020
CIK No. 0001722482
Dear Mr. Stubblefield:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Joseph Kaufman

SecProbe.io